精神分裂症患者脑源性神经营养因子与多巴胺D1受体基因交互作用研究

目的 探讨多巴胺D1受体(DRD1)与精神分裂症的关系是否与脑源性神经营养因子(BDNF)有关.方法 选取BDNF基因Val66Met位点(rs6562)以及DRD1基因5个标签单核苷酸多态性(SNP)(rs4532、rs5326、rs2168631、rs6882300和rs267418),采用TaqMan探针SNP基因分型技术对340例精神分裂症患者(患者组)和375名健康对照者(对照组)进行检验,使用多因子降维法软件(MDR)分析基因-基因交互作用.结果 以上6个SNP基因型及等位基因频率分布在患者组与对照组之间差异无统计学意义(Ps＞0.0083);MDR分析结果显示,BDNF与DRD1基因交互作用存在于两位点模型(rs6265-rs5326)[OR=1.83,95％可信区间(CI):1.33～2.53;x2=13.91,P=0.0002],三位点模型(rs6265-rs4532-rs6882300)(OR=2.06,95％ CI:1.53～2.78;x2=22.73,P＜0.0001)及四位点模型(rs6265-rs5326-rs2168631-rs6882300)(OR =2.85,95％ CI:2.09 ～ 3.89;x2=44.99,P＜0.0001).结论 精神分裂症患者BDNF与DRD1基因存在交互作用,DRD1在精神分裂症发生过程中的作用可能与BDNF有关.     

脑源性神经营养因子基因多态性与强迫症的关联研究

目的:探讨脑源性神经营养因子(BDNF)基因与强迫症(OCD)的关联性。方法:190例OCD患者和309个健康对照为研究对象,通过聚合酶链式反应与限制性片段长度多态性(PCR-RFLP)基因分型技术对BDNF基因标签单核苷酸多态性(SNP)位点rs6265进行基因分型。以耶鲁-布朗强迫量表(Y-BOCS)评定OCD患者的病情。结果:OCD组和对照组之间rs6265位点的基因型和等位基因频率分布差异无统计学意义(P>0.05)。在起病年龄和性别方面基因型和等位基因频率分布差异也无统计学意义(P>0.05)。结论:BDNF基因rs6265多态性与OCD可能没有关联。     

神经型烟碱乙酰胆碱受体α7亚单位基因和儿茶酚-O-甲基转移酶基因多态性与精神分裂症的关联研究

目的 探讨CHRNA7、COMT基因多态性与精神分裂症的相关关系.方法 采用聚合酶链反应及聚丙烯酰胺凝胶芯片技术,检测粤东地区精神分裂症患者(140例)与正常对照者(100例)CHRNA7基因3个单核苷酸多态性位点(rs2337980、rs 1909884、rs883473)和COMT基因3个单核苷酸多态性位点(rs4680、rs737865、rs165599),并对分型结果进行测序鉴定.结果 所有位点的单核苷多态性与精神分裂症发病风险无关联(均P＞0.05).结论 在中国粤东地区CHRNA7基因3个位点(rs2337980、rs 1909884、rs883473)和COMT基因3个位点(rs4680、rs737865、rs165599)的基因多态性可能与精神分裂症无关,但此结论尚需要进一步扩大样本量进行验证.     

脑源性神经营养因子基因多态性与精神分裂症及其认知功能的关联研究

目的:探讨脑源性神经营养因子(BDNF)基因多态性与中国汉族精神分裂症(SCZ)发病及其认知功能的关系。方法:对354例SCZ患者(SCZ组)和416名健康对照人群(正常对照组)的BDNF基因4个多态性位点(rs7482257、rs7483883、rs1491850、rs16917234)进行基因分型;采用重复性成套神经心理状态测验(RBANS)对SCZ组及正常对照组进行认知功能评估。结果:SCZ组RBANS注意分、言语分、视觉广度分、即刻记忆分、延迟记忆分及总分明显低于正常对照组(F=1. 40,F=16. 38,F=96. 99,F=41. 12,F=114. 40,F=65. 23; P均0. 001)。两组BDNF基因4个多态性位点的等位基因(χ2=0. 37～2. 80)、基因型(χ2=1. 06～5. 77)及单体型(χ2=0. 224～2. 979)分布频率比较差异无统计学意义(P均 0. 05)。在SCZ组中,BDNF基因rs7482257不同基因型间视觉广度因子评分差异有统计学意义(F=3. 79,P=0. 024)。结论:BDNF基因多态性可能与SCZ易感性无关联; BDNF基因rs7482257位点的CC基因型可能与SCZ的视觉广度损害有关。     

IL18R1基因多态性与中国汉族精神分裂症的关联性分析

目的:探讨IL18受体IL18R1基因多态性与中国汉族精神分裂症的关系。方法:采用病例对照研究方法,选取1 174例精神分裂症患者(病例组)与1 120名正常健康对照者(对照组),利用连接酶检测-聚合酶链反应(LDR-PCR)方法对IL18R1基因多态位点rs1035130进行基因分型,观察其等位基因及基因型与精神分裂症发病风险的关系。结果:rs1035130的基因型与等位基因频率在病例组与正常对照组中的分布差异无统计学意义(P0.05)。结论:IL18R1基因rs1035130多态性可能与中国汉族精神分裂症无关。     

精神分裂症锚蛋白重复序列3基因多态性及表达研究

目的探讨锚蛋白重复序列3(ankyrin repeat 3,ANK3)基因多态性和基因表达与精神分裂症的关系。方法采用Taq Man探针等位基因分型技术对456例中国汉族精神分裂症患者(患者组)和495名正常对照者(对照组)ANK3基因多态性位点rs10994336、rs10994359进行基因分型,并对基因型、等位基因、单体型频率进行比较;然后采用Taq Man探针及实时荧光定量PCR方法检测另外30例急性期精神分裂症患者和26名正常对照外周血ANK3基因m RNA的表达水平。结果患者组与对照组rs10994336和rs10994359基因型、等位基因频率分布的差异无统计学意义(P0.05)。单体型分析显示,由rs10994336-rs10994359组成单体型C-C、C-T、T-C的频率分布在患者组与对照组间差异无统计学意义(P0.05)。与对照组相比,急性期精神分裂症患者外周血ANK3基因的m RNA表达水平略高,但差异无统计学意义(P0.05)。结论本研究未发现ANK3基因位点rs10994336、rs10994359多态性与精神分裂症的关联,急性期精神分裂症患者外周血中ANK3基因的表达水平未见异常。     

细胞色素氧化酶CYP1A2基因多态性与利培酮治疗汉族精神分裂症患者疗效的关联研究

目的:探对细胞色素氧化酶CYP1A2基因多态性与利培酮治疗汉族精神分裂症患者疗效的相关性。方法:给予93例汉族精神分裂症患者单一利培酮治疗12周;治疗前后阳性与阴性症状量表(PANSS)、个人和社会功能量表(PSP)及认知功能评估;采用微测序分型技术(SNa Pshot SNP)检测患者及100名汉族正常对照者(对照组)CYP1A2基因5个位点(rs2069514,rs2472304,rs35694136,rs4646427,rs762551)多态性,分析CYP1A2基因多态性与利培酮疗效的关系。结果:两组间5个多态性位点的基因型、等位基因频率及SNPs单倍型比较差异无统计学意义;5个多态性位点不同基因型患者间的临床疗效比较差异无统计学意义;多重线性回归分析发现部分多态性位点与利培酮治疗精神分裂症后阴性症状、一般病理学症状、PANSS总分、注意转移力、注意集中力的疗效有关。结论:未发现细胞色素氧化酶CYP1A2多态性是汉族精神分裂症的易感基因相关证据;CYP1A2基因多态性与利培酮治疗的疗效相关。     

脑源性神经营养因子基因多态性与广泛性焦虑症、强迫症的关联研究

目的 探讨脑源性神经营养因子(Brain-Derived Neurotrophic Factor,BDNF)基因与广泛性焦虑症(Generalizea-Anxiety Disorder,GAD)、强迫症(Obsessive-Compulsive Disorder,OCD)的关联性.方法 以上海及周边地区汉族人群108例GAD患者、148例OCD患者和94名健康对照为研究对象,通过TaqMan探针SNP基因分型技术对BDNF基因及基因上游10kb区域的标签单核苷酸多态性(Single nucleotide polyrmorphism,SNP)位点rs6265和rs11030101进行基因分型.同时以汉密尔顿焦虑量表(HAMA)和耶鲁-布朗强迫量表(Y-BOCS)分别评定GAD和OCD患者的病情.结果 GAD组和对照组之间rs6265位点和rs11030101位点的基因型和等位基因频率分布差异无统计学意义(P＞0.05),表明GAD与两个位点不存在关联.同样,也未见OCD与rs6265位点和rs11030101位点的基因型及等位基因存在关联(P＞0.05),GAD和OCD与上述两个位点的单倍型也未见关联(P＞0.05).在GAD组、OCD组内,上述位点的不同基因型组患者首次发病年龄、HAMA或Y-BOCS评分的差异均无统计学意义(P＞0.05).结论 不支持BDNF基因rs6265和rs11030101多态性与GAD或OCD相关.     

中国黑龙江地区汉族人群FK506结合蛋白5基因多态性与精神分裂症的关联研究

目的:探讨中国黑龙江地区汉族人群FK506结合蛋白5(FKBP5)基因多态性与精神分裂症的关系。方法:采用SNaPshot测序法检测和分析49例汉族精神分裂症患者(患者组)和49名汉族健康对照者(对照组)的FKBP5基因rs3800373、rs1360780、rs9296158和rs9470080位点基因型和等位基因频率。结果:FKBP5 rs3800373位点基因型频率两组间差异有统计学意义(P0.05); Logistic回归分析显示,FKBP5基因rs3800373位点TT基因型携带者精神分裂症发生风险明显高于GT基因型携带者(95%CI:0.117～0.756,P=0.01)。结论:FKBP5基因rs3800373位点基因多态性可能与中国黑龙江地区汉族人群精神分裂症发病风险有关。     

精神分裂症与G72基因多态性的关联分析

目的:探讨精神分裂症与G72基因多态性的关系,是否有混合家族史精神分裂症在G72基因多态性的区别。方法:采用聚合酶链反应技术分别检测162例无混合家族史精神分裂症、62例有混合家族史精神分裂症、88名正常对照的G72基因单核苷酸多态性rs947267、rs2181953,进行关联分析。结果:不同性别及发病年龄的无混合家族史精神分裂症组与对照组rs947267、rs2181953基因型及等位基因分布差异均无显著性(P均>0.05);不同性别及发病年龄的有混合家族史精神分裂症组与对照组rs947267基因型及等位基因分布差异无显著性(P>0.05);不同性别及早发型(发病年龄≤25岁)有混合家族史精神分裂症组与对照组rs2181953基因型及等位基因分布差异无显著性(P>0.05);晚发型(发病年龄>25岁)有混合家族史精神分裂症与对照组rs2181953基因型及等位基因分布差异显著(χ2=9.121,P=0.01与χ2=6.804,P=0.01),基因型A/A、T/T及等位基因A、T的OR值分别为7.083(P=0.007)、0.357(P=0.049)、2.531(P=0.009)、0.395(P=0.009)。结论:G72基因多态性可能与晚发型有混合家族史精神分裂症存在关联,其中rs2181953的A/A基因型与A等位基因是危险因子。     

Serum brain-derived neurotrophic factors in Taiwanese patients with drug-naïve first-episode schizophrenia: Effects of antipsychotics

Objectives: Brain-derived neurotrophic factors (BDNF) are known to be related to the psychopathology of schizophrenia. However, studies focussing on drug-naïve first-episode schizophrenia are still rare.

Methods: Over a 5-year period, we investigated the serum BDNF levels in patients with first-episode drug-naïve schizophrenia and compared them to age- and sex-matched healthy controls. We also explored the association between antipsychotic doses, positive and negative syndrome scale (PANSS) scores, and serum BDNF levels before and after a 4-week antipsychotic treatment.

Results: The baseline serum BDNF levels of 34 patients were significantly lower than those of the controls (df?=?66, P?=?.001). Although the PANSS scores of 20 followed-up patients improved significantly after antipsychotic treatment, the elevation of the serum BDNF levels was not statistically significant (P?=?.386). In addition, Pearson’s correlation test showed significant correlations between pre-treatment negative scale scores and percentage changes in BDNF (P?=?.002).

Conclusions: The peripheral BDNF levels in Taiwanese patients with drug-naïve first-episode schizophrenia, compared with healthy controls, did not elevate after antipsychotic treatment, and pre-treatment negative symptoms played a pivotal role in trajectories of serum BDNF levels. Large samples will be needed in future studies to verify these results.     

抑郁症患者自杀行为与血清脑源性神经营养因子水平的关系

目的:探讨血清脑源性神经营养因子(BDNF)水平与抑郁症患者自杀行为之间的关系.方法:采用酶联吸附反应方法对有自杀行为的21例抑郁症患者(自杀组)、无自杀行为的52例抑郁症患者(非自杀组)以及80例正常人(对照组)血清的BDNF进行检测,应用汉密尔顿抑郁量表(HAMD)对抑郁症患者的抑郁症状进行评定. 结果:抑郁症患者...     

Decreased levels of serum brain-derived neurotrophic factor in female patients with eating disorders.

BACKGROUND: Several lines of evidence suggest that brain-derived neurotrophic factor (BDNF) plays a role in the regulation of eating behavior. Because of its role in eating behavior, which is especially relevant to eating disorders, BDNF is an attractive candidate for investigation of potential biological markers of eating disorders such as bulimia nervosa (BN) and anorexia nervosa (AN). METHODS: We enrolled 18 female patients with BN, 12 female patients with AN, and 21 age-matched female normal control subjects in this study. Eating-related psychopathology and depressive symptoms were evaluated using the Bulimic Investigatory Test, Edinburgh (BITE) and the Hamilton Depression Rating Scale (HDRS). Serum BDNF levels were measured by a sandwich enzyme-linked immunosorbent assay. RESULTS: Serum levels of BDNF in the patients with AN or BN were significantly (p<.0001) decreased compared with those of normal control subjects, and serum BDNF levels in the patients with AN were significantly (p=.027) lower than those in patients with BN. A significant positive correlation (r=.378, p=.006) between serum BDNF levels and body mass index in all of the subjects was detected. Furthermore, there was a significant positive correlation (r=.435, p=.015) between the BITE symptom scale score and HDRS in these patients. CONCLUSIONS: The present study suggests that BDNF may play a role in the pathophysiology of eating disorders.     

Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial

The purpose of the present study was to evaluate the clinical effectiveness of kamishoyosan for antipsychotic-induced tardive dyskinesia, and to investigate the relationship between tardive dyskinesia and serum brain-derived neurotrophic factor (BDNF) levels. Sixty-nine schizophrenia patients were enrolled; of these, 49 presented with tardive dyskinesia while the remaining 20 patients showed no tardive dyskinesia. The tardive dyskinesia group was treated for 16 weeks with kamishoyosan and assessed using the abnormal involuntary movement scale. The abnormal involuntary movement scale scores in the tardive dyskinesia group were evaluated at baseline and after 4, 8, and 16 weeks of treatment. The BDNF levels of all subjects were measured at baseline in order to compare differences in serum BDNF levels between the tardive dyskinesia group and the non-tardive dyskinesia group, and to correlate the severity of tardive dyskinesia and serum BDNF in the tardive dyskinesia group. A meaningful reduction in total abnormal involuntary movement scale scores was observed in the tardive dyskinesia group treated with kamishoyosan at 4, 8, and 16 weeks of treatment (P < 0.01). No significant differences in serum BDNF levels were detected between the tardive dyskinesia group and the non-tardive dyskinesia group at baseline. Furthermore, no significant correlation was seen between the severity of tardive dyskinesia and serum BDNF levels. The present study suggests that kamishoyosan might be a promising adjunctive treatment for antipsychotic-induced tardive dyskinesia.     

Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment

Brain-derived neurotrophic factor (BDNF) has been suggested to be involved in the etiology of schizophrenia. There is a line of evidence that disruption of neurotrophins could play a role in the etiology of schizophrenia, and antipsychotics show their effect by altering levels of neurotrophins. The aim of this study was to evaluate the effect of antipsychotics on serum BDNF levels and their relationship with the symptoms in patients with schizophrenia. Twenty-two schizophrenia patients were enrolled in the study. The control group consisted of 22 age- and sex-matched physically and mentally healthy volunteers (7 male, 15 female). Serum BDNF levels and the positive and negative syndrome scale (PANSS) scores were recorded at baseline and after 6 weeks of treatment. Serum BDNF levels were also recorded in the control group. Schizophrenia patients who failed to meet 30% improvement in PANSS score were excluded from the study. The baseline serum BDNF levels of schizophrenia patients were lower than those of controls (t = 4.56; df = 21; p < 0.001). There was no correlation between serum BDNF levels and PANSS scores in patients with schizophrenia (p > 0.05). Although PANSS (for positive symptoms p < 0.001, for negative symptoms p < 0.001) and general psychopathology (t = 20.9; df = 22; p < 0.001) scores improved significantly after 6 weeks of antipsychotic treatment; there was no change in BDNF levels in patients' serum (p > 0.05). Our results support the view that BDNF would be associated with schizophrenia. However, we could not conclude that treatment with antipsychotics alters serum BDNF levels in patients with schizophrenia.     

Serum concentrations of nerve growth factor and brain-derived neurotrophic factor in depressed patients before and after antidepressant treatment

INTRODUCTION: Stress, glucocorticoids and anti-depressant treatment have been found to modulate the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Recent research suggests that serum BDNF concentration is reduced in depression and that successful antidepressant treatment leads to an increase in serum BDNF concentration. METHODS: We studied depressed patients receiving a standardized antidepressant treatment with either 150 mg amitriptyline (n=20) or 40 mg paroxetine (n=20) for 36 days in a prospective design. Changes in the concentrations of serum neurotrophins and salivary cortisol in response to antidepressant treatment were assessed. RESULTS: Independent of clinical efficacy there was a significant 'treatment' by 'medication' interaction effect on BDNF serum concentrations that indicated a decline of BDNF by 12% in paroxetine-treated patients while there was an increase by 13% in amitriptyline-treated patients. Neither antidepressant altered NGF concentrations. The changes in cortisol and neurotrophin concentrations were not related. DISCUSSION: Changes in BDNF serum concentrations as a result of antidepressant therapy depend on the antidepressant instead of being a general characteristic of response to antidepressant treatment.     

帕罗西汀联合心理治疗对产后抑郁患者负面情绪及睡眠质量的影响

目的 探讨帕罗西汀联合心理治疗对产后抑郁患者负面情绪及睡眠质量的影响.方法 选取2017年1月～2019年6月我院收治的111例产后抑郁症患者作为主要研究对象.按随机数字表法将研究对象随机分为观察组和对照组,两组患者均接受心理治疗.在此基础上,对照组(55例)给予马普替林治疗,观察组(56例)给予帕罗西汀治疗,观察对比...     

Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia

OBJECTIVE: Brain-derived neurotrophic factor (BDNF) is stress-responsive and has been implicated in a number of disparate neuropsychiatric disorders. Glucocorticoid antagonists have been shown to have beneficial effects on mood and cognitive function in bipolar disorder but not in schizophrenia. The aim of the present study was to investigate BDNF levels in patients with bipolar disorder and schizophrenia before and after treatment with the glucocorticoid receptor antagonist mifepristone. METHODS: Peripheral BDNF levels were measured in patients with bipolar disorder (n=20), schizophrenia (n=20) and 14 matched healthy controls following 7 days of adjunctive mifepristone (600 mg day(-1)) treatment in a double-blind, placebo-controlled crossover design study. RESULTS: Baseline BDNF values were similar in both patient groups and in healthy controls. Following treatment with mifepristone, cortisol levels were significantly increased and BDNF levels decreased in both schizophrenia and bipolar disorder. A significant correlation existed between change in cortisol level and change in BDNF levels following mifepristone treatment in schizophrenia, but not in bipolar disorder. CONCLUSION: Differing BDNF responses to increasing cortisol levels between patients with schizophrenia and with bipolar disorder may reflect underlying pathophysiological mechanisms.     

精神分裂症自杀未遂者脑源性神经营养因子研究

目的:探讨影响精神分裂症自杀未遂患者脑源性神经营养因子(BDNF)水平的相关因素。方法:采用横断面病例-对照研究设计。研究包括精神分裂症自杀未遂组20例,精神分裂症无自杀行为组28例,正常对照组30名。采用酶联免疫吸附试验法测定血清BDNF浓度。采用简明精神病评定量表(BPRS)和自杀意图自评量表(SIOSS)对患者组进行评定。比较各组BDNF水平及其与相关因素之间的关系。结果:三组间BDNF水平差异有统计学意义(F=32.395,P<0.01)。Post-hoc分析发现,精神分裂症自杀未遂组BDNF水平[(51.3±11.1)pg/ml]显著低于精神分裂症无自杀行为组[(67.7±20.8)pg/ml](P<0.05),而精神分裂症无自杀行为组BDNF水平也低于正常对照组[(111.3±39.0)pg/ml](P<0.01)。自杀未遂组的血清BDNF水平与自杀严重程度呈负相关(r=-0.836,P<0.01)。结论:精神分裂症自杀未遂患者BDNF水平低于精神分裂症无自杀行为患者和正常人群;BDNF可能是参与精神分裂症自杀病理生理机制的一种重要物质。     

重复经颅磁刺激对首发精神分裂症患者血清脑源性神经营养因子的影响

目的分析高频重复经颅磁刺激(rTMS)对首发精神分裂症患者血清脑源性神经营养因子(BDNF)的影响。方法选取82例以阴性症状为主的首发精神分裂症患者,使用随机数表将82例患者分为对照组41例和观察组41例,2组均使用常规药物治疗,观察组同时予以真刺激治疗,对照组予以假刺激治疗,对比2组治疗结果。结果治疗4周后观察组PANSS(阳性和阴性症状量表)总分、阴性症状评分、一般病理评分及血清BDNF浓度均优于治疗前,且优于对照组(P0.05);对照组PANSS总分、阴性症状评分、阳性症状评分、一般病理评分及血清BDNF浓度与之前相比无明显变化(P0.05)。观察组BDNF浓度变化与PANSS总分及各因子的变化无明显相关性(P0.05)。结论rTMS可显著增加首发精神分裂症患者的血清BDNF水平,但血清BDNF水平变化与其临床症状的改善无明显相关性。